99 related articles for article (PubMed ID: 18465342)
1. Vinorelbine as first-line or second-line therapy for advanced breast cancer: a Phase I-II trial by the Danish Breast Cancer Co-operative Group.
Langkjer ST; Ejlertsen B; Mouridsen H; Andersen J; Nielsen MM; Møller KA; Madsen EL; Haarh V;
Acta Oncol; 2008; 47(4):735-9. PubMed ID: 18465342
[TBL] [Abstract][Full Text] [Related]
2. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
[TBL] [Abstract][Full Text] [Related]
3. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy.
Freyer G; Delozier T; Lichinister M; Gedouin D; Bougnoux P; His P; Imadalou K; Trillet-Lenoir V
J Clin Oncol; 2003 Jan; 21(1):35-40. PubMed ID: 12506167
[TBL] [Abstract][Full Text] [Related]
5. A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma.
Kulke MH; Muzikansky A; Clark J; Enzinger PC; Fidias P; Kinsella K; Michelini A; Fuchs CS
Cancer Invest; 2006; 24(4):346-50. PubMed ID: 16777685
[TBL] [Abstract][Full Text] [Related]
6. Vinorelbine as palliative therapy in advanced breast cancer.
Gasco M; Gardin G; Repetto L; Campora E; Rosso R
Anticancer Res; 1997; 17(2B):1431-3. PubMed ID: 9137510
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer.
Blasinska-Morawiec M; Tubiana-Mathieu N; Fougeray R; Pinel MC; Bougnoux P
Breast; 2013 Feb; 22(1):58-63. PubMed ID: 23195794
[TBL] [Abstract][Full Text] [Related]
8. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer.
Mlineritsch B; Schabel-Moser R; Andel J; Fridrik M; Moik M; Mayer P; Russ G; Rass C; Greil R;
Onkologie; 2009 Feb; 32(1-2):18-24. PubMed ID: 19209014
[TBL] [Abstract][Full Text] [Related]
9. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer.
Rossi A; Gridelli C; Gebbia V; Rosati G; Tortoriello A; Maione P; Borsellino N; Rossi N; Pisano A; Colantuoni G; Iaffaioli RV; Castaldo V; Manzione L
Anticancer Res; 2003; 23(2C):1657-64. PubMed ID: 12820437
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.
Ma CD; Chen CM; Chen XS; Liu GY; Di GH; Wu J; Lu JS; Yang WT; Chen JY; Shao ZM; Shen ZZ; Shen KW
Anticancer Res; 2008; 28(5B):3093-7. PubMed ID: 19031963
[TBL] [Abstract][Full Text] [Related]
12. Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules.
Terzoli E; Nisticò C; Fabi A; Milella M; Bria E; D'Ottavio AM; Vaccaro A; Vanni B; Garufi C; Ferraresi V; Giannarelli D; Papaldo P; Carlini P; Izzo F; Cognetti F
J Exp Clin Cancer Res; 2004 Jun; 23(2):207-13. PubMed ID: 15354404
[TBL] [Abstract][Full Text] [Related]
13. 5-year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: a multicentre phase II study.
Barni S; Visini M; Piazza E; Ionta MT; Ardizzoia A; Arnoldi E; Fava S; Pinotti G; Torretta F; Corradini G; Villa S; Nosenzo AM; Massidda B; Cazzaniga ME
Anticancer Res; 2007; 27(4C):3019-24. PubMed ID: 17695490
[TBL] [Abstract][Full Text] [Related]
14. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
15. Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer.
Winer EP; Chu L; Spicer DV
Semin Oncol; 1995 Apr; 22(2 Suppl 5):72-8; discussion 78-9. PubMed ID: 7740337
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
Mukai H; Masuda N; Ishiguro H; Mitsuma A; Shibata T; Yamamura J; Toi M; Watabe A; Sarashina A; Uttenreuther-Fischer M; Ando Y
Cancer Chemother Pharmacol; 2015 Oct; 76(4):739-50. PubMed ID: 26254023
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.
Gomez HL; Doval DC; Chavez MA; Ang PC; Aziz Z; Nag S; Ng C; Franco SX; Chow LW; Arbushites MC; Casey MA; Berger MS; Stein SH; Sledge GW
J Clin Oncol; 2008 Jun; 26(18):2999-3005. PubMed ID: 18458039
[TBL] [Abstract][Full Text] [Related]
19. [Relation of dose intensity and efficacy, toxicity in paclitaxel as a single agent for advanced breast cancer].
Liu F; Jiang ZF; Song ST; Liu XQ; Wang T; Yan M; Zhang SH; Hao CF; Sun JZ; Shen G
Zhonghua Zhong Liu Za Zhi; 2005 Jan; 27(1):56-8. PubMed ID: 15771802
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.
Rothenberg ML; Liu PY; Wilczynski S; Nahhas WA; Winakur GL; Jiang CS; Moinpour CM; Lyons B; Weiss GR; Essell JH; Smith HO; Markman M; Alberts DS
Gynecol Oncol; 2004 Dec; 95(3):506-12. PubMed ID: 15581954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
